证券代码：300717 证券简称：华信新材 公告编号：2025-022 江苏华信新材料股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 江苏华信新材料股份有限公司（以下简称"公司"）2024年年度权益分派方案已获 2025年5月15日召开的2024年度股东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案的情况 1、2024年年度权益分派方案已获2025年5月15日召开的股东大会审议通过，2024年 年度权益分派方案为：以2024年12月31日公司总股本102,775,000股为基数，以公司可 分配利润向全体股东每10股分配现金股利2元（含税），合计派发现金股利人民币2055.5 万元(含税)，本次不送红股，不以资本公积金转增股本。在利润分配方案实施前，公司 总股本如发生变化，将按照分配总额不变的原则对分配比例进行相应调整。 4、本次权益分派距离股东大会通过的权益分派方案时间未超过 两个月。 2、公司总股本为102,775,000股，自分派方案披露至实施期间不会发生变化。 3、本次实施的利 ...

证券代码：300717 证券简称：华信新材 公告编号：2025-021 江苏华信新材料股份有限公司 法定代表人：李振斌 成立日期：2004 年 03 月 15 日 注册资本：人民币 500.0000 万元整 关于控股股东变更名称、住所及经营范围并完成工商变更登记的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 江苏华信新材料股份有限公司（以下简称"公司"）于近日收到公司控股股东上海 华智信科技有限公司（原用名：江苏华智工贸实业有限公司）通知，获悉其名称、住所 及经营范围发生了变更，上述变更事项已完成工商变更登记，并已取得由上海市宝山区 市场监督管理局核发的《营业执照》，变更后的《营业执照》主要内容如下： 统一社会信用代码：913203817596693752 名称：上海华智信科技有限公司 类型：有限责任公司（自然人投资或控股） 住所：上海市宝山区祁连山路 1588 号 3 幢 9 层 908 室 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技 术推广；数字技术服务；机械设备研发；机械设备销售；软件开发；软件销售；信息技 术咨 ...

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

江苏华信新材料股份有限公司（以下简称"公司"）全资子公司江苏华信高新材料 有限公司（以下简称"华信高新"）于近日收到国家知识产权局颁发的 2 项实用新型专 利授权证书，具体情况如下。 证券代码：300717 证券简称：华信新材 公告编号：2025-020 江苏华信新材料股份有限公司 关于全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 | 专利名称 | 专利号 | | 专利申请 | | | 授权公告 | | 专利 | 专利 | | 证书号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 日 | | | 日 | | | 类型 | 权人 | | | | 一种片材堆垛除静电 | ZL2024221363 | 2024 | 年 | 8 | 2025 | 年 | 5 | 实用 | 华信 | 第 | 22854425 | | 装置 | 34.3 | 月 | 30 | 日 | 月 | 13 | 日 | 新型 | 高新 | | 号 ...

证券代码：300717 证券简称：华信新材 公告编号：2025-019 监事会 2025 年 5 月 26 日 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 江苏华信新材料股份有限公司（以下简称"公司"）监事会于近日收到公司股东代 表监事吕晓伟先生的书面辞职申请，吕晓伟先生原定任期至第四届监事会届满，因个人 原因申请辞去公司第四届监事会监事职务，辞去职务后，吕晓伟先生将继续在公司担任 其他职务。 根据《公司法》《公司章程》等规定，吕晓伟先生离任后公司监事会成员低于法定 人数，为保证公司监事会的正常运作，其辞职申请自公司股东大会选举新任监事或取消 监事会后生效。在此期间，吕晓伟先生仍将按照有关法律法规的要求继续履行其监事职 责。 截至本公告披露日，吕晓伟先生未直接持有公司股份，不存在应当履行而未履行的 承诺事项。在其就任时确定的任期内和任期届满后六个月内，将继续严格按照《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易 所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股份》等 法律法规进行股份管 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于江苏华信新材料股份有限公司 2024 年度股东大会的法律意见书 康达股会字【2025】第 0178 号 致：江苏华信新材料股份有限公司 北京市康达律师事务所（以下简称"本所"）接受江苏华信新材料股份有限 公司（以下简称"公司"）的委托，指派本所律师参加公司 2024 年度股东大会 （以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、 ...

江苏华信新材料股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、召开会议的情况 证券代码：300717 证券简称：华信新材 公告编号：2025-018 1、会议召开时间 现场会议召开时间：2025 年 5 月 15 日 14:30 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 15 日（星期四）9:15～9:25，9:30～11:30 和 13:00～15:00；通过互联网投票系统 投票的具体时间为：2025 年 5 月 15 日（星期四）上午 9:15 至下午 15:00 期间的任意 时间。 2、现场会议地点：江苏省新沂市珠江路 18 号 401 会议室。 3、会议召开的方式：本次会议以现场投票与网络投票相结合的方式召开 4、会议召集人：公司董事会 5、会议主持人：董事长李振斌先生 6、本次会议的召开符合《中华人民共和国公司法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等法律、法规及规范 性文件的规定。 7、会议出席情况 参 ...

证券代码:300717 证券简称:华信新材 编号： 2025001 江苏华信新材料股份有限公司 投资者关系活动记录 12、去年公司研发投入占比如何？研发投入是否产生了实质性效应？ 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他 （ ） 参与单位名称 及人员姓名 参与公司 2024 年度网上业绩说明会的投资者 时间 2025 年 4 月 28 日 15:00-17:00 地点 "中国证券报·中证网"(http://www.cs.com.cn/roadshow/)（本次 业绩说明会采用网络远程方式举行） 上市公司接待 人员 董事长、总经理：李振斌 董事、董事会秘书：束珺 财务总监：杨希颖 独立董事：刘涛 投资者关系活 动主要内容介 绍 与投资者进行互动交流和沟通，就投资者关注的主要问题进行了答复。 1、华信公司 2024 年度营收同比基本持平，净利润同比增加超过 23%，主要原 因是什么？ 回复：投资者您好，主要原因一是产品结构持续优化，传统材料销售同比 下降，PETG、PC、生物基材料及循环再生材料等环保材料销售同比上升， ...

Financial Performance - The company's revenue for Q1 2025 was ¥88,799,636.96, representing a 12.10% increase compared to ¥79,215,518.87 in the same period last year[5] - Net profit attributable to shareholders for Q1 2025 was ¥15,889,462.01, a significant increase of 48.84% from ¥10,675,428.43 in Q1 2024[5] - The net profit after deducting non-recurring gains and losses was ¥15,665,829.03, reflecting a 52.57% increase compared to ¥10,268,135.37 in the previous year[5] - Total operating revenue for the current period reached ¥88,799,636.96, an increase of 12.5% compared to ¥79,215,518.87 in the previous period[23] - Net profit for the current period was ¥15,834,008.72, representing a 48.3% increase from ¥10,675,428.43 in the previous period[25] - Earnings per share (EPS) increased to ¥0.15 from ¥0.10, reflecting a 50% growth[26] Assets and Liabilities - The company's total assets increased by 5.98% to ¥984,042,110.13 from ¥928,557,596.01 at the end of the previous year[5] - The total current assets are CNY 441,858,976.01, up from CNY 407,854,245.16 at the beginning of the period[20] - The total current liabilities increased to CNY 241,088,407.79 from CNY 203,802,303.88[21] - The total liabilities increased to ¥261,333,193.24 from ¥224,022,687.84, indicating a growth of 16.7%[22] - Total equity attributable to shareholders rose to ¥720,424,379.23, up from ¥704,534,917.22, marking a 2.2% increase[22] Cash Flow - Cash flow from operating activities showed a net outflow of ¥13,570,828.92, an improvement of 18.93% compared to the outflow of ¥16,739,657.96 in Q1 2024[5] - Cash flow from operating activities showed a net outflow of ¥13,570,828.92, an improvement from a net outflow of ¥16,739,657.96 in the previous period[28] - Cash and cash equivalents at the end of the period totaled ¥184,549,203.27, compared to ¥164,322,620.46 at the end of the previous period[29] - The cash and cash equivalents at the end of the period are CNY 193,129,883.70, slightly down from CNY 193,534,426.01[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,544[13] - Jiangsu Huazhi Industrial Trade Co., Ltd. holds 48.08% of the shares, totaling 49,413,354 shares[13] - The company has no preferred shareholders or changes in restricted shares during the reporting period[15] - The company has no significant changes in the top 10 shareholders participating in margin financing and securities lending[14] Investments and Projects - The company plans to invest CNY 80 million in a project to produce 5,000 tons of functional membrane materials annually[17] - The company invested ¥32,985,391.95 in fixed assets during the current period, significantly higher than ¥14,569,862.00 in the prior period[28] Other Financial Metrics - The weighted average return on equity rose to 2.23%, up from 1.57% in the same period last year, indicating improved profitability[5] - The accounts receivable increased significantly by 133.90% to ¥24,025,761.33, primarily due to an increase in accepted bills[8] - The company reported a credit impairment loss of ¥2,119,437.44, compared to a gain of ¥2,363,089.57 in the previous period[24] - The company received government subsidies amounting to ¥241,487.87 during the period, contributing to its financial performance[7] - The company reported a 795.28% increase in tax refunds received, amounting to ¥3,306,988.71, due to a rise in VAT refunds[10] Accounting and Governance - The first quarter report has not been audited[30] - The new accounting standards will be implemented starting from 2025[30] - The financial statement items related to the first year of implementation will be adjusted accordingly[30] - The board of directors of Jiangsu Huaxin New Materials Co., Ltd. is represented by the legal representative[31] - The date of the board meeting is not specified in the document[31]

Group 1 - The company Huaxin New Materials (300717) reported a revenue of 88.7996 million yuan for the first quarter of 2025, representing a year-on-year growth of 12.10% [1] - The net profit for the same period was 15.8895 million yuan, showing a significant year-on-year increase of 48.84% [1]